About InnoCare Pharma Company

The company is a commercialized biomedical high-tech company. It was co-founded in 2015 by Dr. Cui Jisong, who has rich experience in new drug development and enterprise management, and Academician Shi Yigong, a world-famous structural biologist. We develop innovative drugs for patients with malignant tumors and autoimmune diseases, so that innovative results can benefit more patients. The company is an innovative biomedical enterprise with excellent independent research and development capabilities as the core driving force. It has comprehensive R&D and commercialization capabilities, focuses on fields such as tumors and autoimmune diseases that have huge unmet clinical needs, and develops best-in-class or first-of-its-kind drugs with breakthrough potential in the global market. Main products: obutinib, ICP-B04, ICP-248, ICP-B02, ICP-490, ICP-B05, ICP-332, ICP-488, ICP-B02, ICP-923, ICP-723,, ICP-192, etc. ICP-189